Skip to main content

Max Masucci

Analyst

ROTH Capital Partners

Equibles does not estimate personal net worth.

About Max Masucci

Max Masucci is recorded as Analyst at ROTH Capital Partners. Max Masucci has spoken on 5 earnings calls across 5 companies, most recently for 908 Devices Inc. on August 11, 2026. Those appearances were for 908 Devices Inc. (MASS), Alpha Teknova, Inc. (TKNO), Biodesix Inc (BDSX), Exagen Inc. (XGN) and Castle Biosciences Inc (CSTL). The companies whose calls Max Masucci spoke on are classified in the Healthcare sector.

Max Masucci on recent calls

“If you look across the first 110 Viper placements, what trends have you seen in terms of single versus multi-device orders? What percentage of the Viper placements have been to existing FTIR customers versus customers that are new to 908?”
Analyst — ROTH Capital Partners, 908 Devices Second Quarter 2026 Financial Results Conference Call ·
“BuildTech, so appreciate the detail in the release this morning. Just curious how the quote volume has trended since the June beta launch through early August here.”
Analyst — ROTH Capital Partners, Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026 ·
“So, you know, first half, 38% year-over-year growth in revenue. If you look at the full-year range, it implies, you know, second-half growth, like around 16% at the midpoint, 22% at the high end.”
Analyst — ROTH Capital Partners, Biodesix Q2 2026 Earnings Conference Call ·
“First on Salesforce productivity, you know, the five territory reps you hired in 2025, I believe are beyond the six to nine month ramp. Just curious if those reps provided a noticeable boost to volume growth in Q2, or if the strength was more broad based, you know, across the entire force.”
Analyst — ROTH Capital Partners, Q2 2026 Earnings Call ·
“So first question on Advance ADTX, nice to see the unanimous panel vote for the crosswalk. I would love to get your initial thoughts on the rate associated with the crosswalk, you know, whether the decision matched your expectations and just any updated expectations around the transition to a full commercial launch.”
Analyst — ROTH Capital Partners, Castle Biosciences Q2 2026 Earnings Call ·

Affiliation history

  • ROTH Capital Partners

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity